'Drug distribution' is the broader concept of in-vivo spatial allocation; 'drug tissue distribution imaging' focuses more on differences among different tissue regions within an organ (e.g., portal area vs central vein area of liver, cortex vs medulla of kidney, tumor vs paratumor). The in-situ nature of MSI allows these experiments, originally needing region-by-region sampling and separate homogenization, to be directly presented with molecular images on the same section.
The Neo-Source MSI DPI lists pharmacokinetics as a key area, explicitly used for new drug R&D, distribution studies of drugs and metabolites in different organs at different times, drug quantification and drug discovery; its matrix-free, low-ion-suppression design and direct analysis of complex samples fit tissue distribution research requiring many time-point and dose-group comparisons.
First, target-site confirmation: does the drug enter the intended tissue? Second, toxicity hints: abnormal enrichment in non-target tissues (e.g., renal cortex, myocardium) can warn in advance; third, formulation evaluation: tissue distribution differences under different formulations, nanocarriers or administration routes; fourth, metabolite tracking: do parent drug and metabolites co-localize.
Tests on animal tissues and plant leaves in DPI applications showed that, in both positive and negative ion modes compared with traditional DESI, more than a hundred additional secondary metabolites could be detected, with overall signal enhanced by 1–3 orders of magnitude, and this sensitivity leap also benefits the tissue distribution detection of low-abundance drugs and metabolites.
A tissue distribution map is meaningful only when overlaid onto histological structures. In practice, MSI sections are often registered with adjacent H&E or IHC sections to judge whether the signal-enhanced region falls on the target cell band or a specific pathological partition. The two Neo-Source imaging sources keep the section intact after imaging for continued H&E or IHC validation.
Matrix-free preparation is especially valuable here: the Neo-Source MSI DPI and MSI LDPI are matrix-free and measure on demand, reducing sample handling from 'half a day at best' to 'measure on demand', significantly accelerating drug screening requiring many tissue-region comparisons.
MSI mainly provides relative spatial distribution and ion-intensity images; absolute quantification requires standard curves or internal standards, considering histological background. It excels at localization and discovery; the gold standard for absolute quantification is often complemented by LC-MS.
Engineered, DPI is compatible with mainstream mass spectrometers from Agilent, AB SCIEX and Thermo (MSI DPI-25A/25S/25T), providing a self-developed titanium-alloy ion transfer tube that does not damage the sample at the front end and is detachable for cleaning, enabling drug tissue distribution imaging to move stably and reproducibly from research projects into quality-control and screening production lines.
To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).